Browsing Tag
Australian Securities Exchange
21 posts
The a2 Milk Company recalls U.S. infant formula batches as cereulide risk raises supply-chain questions
Infant formula trust is fragile. The a2 Milk Company recall shows how one ingredient risk can become a wider supply-chain test.
ASX 200 ends 8-day losing streak as 73% of stocks rebound, only Energy lags
Australia's longest losing streak since 2018 just broke. The bounce is real, but breadth and Energy reversal hint at consolidation, not recovery.
Woodside Energy Q1 revenue rises as WDS pushes Scarborough toward first LNG
Woodside Energy Group Ltd produced less, earned more and kept LNG projects on track. WDS investors now face an execution test.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
DPM Metals (DPM) Q1 2026 production on track as Vareš ramp-up proceeds and Serbia drilling accelerates
DPM Metals reports 84,000 GEO in Q1 2026 as Vareš ramps up and Čoka Rakita drilling accelerates. Full analysis of production, margins and what comes next. Read more.
Can Lumos Diagnostics (ASX: LDX) turn a small Micro-Pak order into proof that its services model really scales?
Lumos Diagnostics has secured a new Micro-Pak manufacturing deal and first order. Read why this matters for ASX:LDX’s revenue mix and strategy.
Can Complii FinTech (ASX: CF1) turn ARR stability into profits?
Complii FinTech Solutions Limited’s H1 FY26 results show whether its rebuilt platform and cost reset can finally unlock SaaS operating leverage. Read the full analysis.
Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.
Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.
Careteq (ASX: CTQ) to divest Embedded Health Solutions for A$5m to stabilise balance sheet
Careteq Limited to sell Embedded Health Solutions for A$5 million, resetting strategy, balance sheet priorities, and ASX compliance risk. Find out what happens next.
Intelligent Monitoring Group (ASX: IMB) expands with BNP Securities – but will the stock react?
Intelligent Monitoring Group (ASX: IMB) buys BNP Securities for A$4.2M, expanding ADT Guard into NSW. See how acquisitive growth is reshaping IMB’s outlook today.